Graviton BioScience Stock

HealthTech

Graviton BioScience is a developer of clinical-stage drugs aimed at treating autoimmune disorders, cancer, and other severe diseases. The company's platform is focused on designing and advancing therapeutics for CNS, autoimmune, fibrotic, and various serious conditions where ROCK2 and its other compounds are crucial in disease pathology. Graviton BioScience offers drug candidates targeting Rho-associated protein kinase, a significant mediator of cellular contractility and fibrosis. This enables customers to potentially access revolutionary treatments for a variety of debilitating illnesses.